SCHEMBL6256841

SCHEMBL6256841

CCOSP(=O)(SOCC)C(CNc1ccc(C)nc1C)c1cc2ccc(OC)cc2s1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 1/20 0.33
SMN1; SMN2 Q16637 5/20 0.31
NPC1 O15118 4/20 0.31
RAB9A P51151 4/20 0.31
MAPT P10636 3/20 0.31
KDM4E B2RXH2 2/20 0.31
MEN1 O00255 4/20 0.31
KMT2A Q03164 4/20 0.31
ALDH1A1 P00352 2/20 0.30
USP2 O75604 1/20 0.30
NFKB1 P19838 1/20 0.30
CASP1 P29466 1/20 0.30
NFKB2 Q00653 1/20 0.30
RELA Q04206 1/20 0.30
HSD17B10 Q99714 1/20 0.30
TP53 P04637 1/20 0.30
MKNK2 Q9HBH9 3/20 0.30
RXFP1 Q9HBX9 1/20 0.30
FLT3 P36888 1/20 0.30
HTT P42858 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6254565 0.86 HSD17B10 (0.37) CA2SMN1; SMN2NPC1RAB9AMAPT
SCHEMBL6324062 0.85 CA2 (0.33) CA2SMN1; SMN2NPC1RAB9AMAPT
SCHEMBL6325868 0.84 HSD17B10 (0.32) CA2SMN1; SMN2NPC1RAB9AMAPT
SCHEMBL6317265 0.83 CA2 (0.32) CA2NPC1RAB9AMAPTHSD17B10
SCHEMBL6256850 0.83 CA2 (0.31) CA2MAPTHSD17B10POLB
SCHEMBL6272796 0.74 WRN (0.31)
SCHEMBL6257326 0.73
SCHEMBL6318976 0.73 CA2 (0.32) CA2
SCHEMBL6256151 0.71
SCHEMBL6308431 0.69 CA12 (0.40) CA2SMN1; SMN2NPC1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143349-A1 Phosphorus containing compounds useful for the regulation of LDL and Lp(a) levels QUATRX PHARMACEUTICALS CO. 2005-06-30 US claimed
WO-2005058330-A1 PHOSPHORUS CONTAINING COMPOUNDS USEFUL FOR THE REGULATION OF LDL AND LP(A) LEVELS QUATRX PHARMACEUTICALS CO. (US) 2005-06-30 WO claimed
US-20050143349-A1 Phosphorus containing compounds useful for the regulation of LDL and Lp(a) levels QUATRX PHARMACEUTICALS CO. 2005-06-30 US disclosed
WO-2005058330-A1 PHOSPHORUS CONTAINING COMPOUNDS USEFUL FOR THE REGULATION OF LDL AND LP(A) LEVELS QUATRX PHARMACEUTICALS CO. (US) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143349-A1 Phosphorus containing compounds useful for the regulation of LDL and Lp(a) levels APOB, LDLR, LPL CA2 2047/4885SMN1; SMN2 4738/4885NPC1 88/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.